We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Office of Generic Drugs (OGD) has about 1,600 applications waiting for approval, and it could take a couple of years to work through the backlog, in part because of the residual solvents rule, according to an FDA official.